Prognostic Value of Altered Signaling Pathways in Chronic Lymphocytic Leukemia
Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Facts About Leukemia: 6 Myths You Might Encounter at Your Practice
It’s useful to be aware of misconceptions your patients might have about leukemia. We debunk 6 common myths.
Dasatinib Tops Imatinib for Ph+ Acute Lymphoblastic Leukemia
Four-year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
No Benefit With Intensified Postinduction in Pediatric Standard-Risk Acute Lymphoblastic Leukemia
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Ofatumumab May Prolong Survival in Relapsed Chronic Lymphocytic Leukemia
Median progression-free survival was 34.2 months in patients who received ofatumumab and 16.9 months in patients who received no additional treatment.
CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Study Finds Real-World Outcomes Differ for Idelalisib in FL and CLL
The analysis revealed that Medicare beneficiaries had different treatment outcomes compared with the trial participants.
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017
Improvement in median overall survival from 5.8 years in 1995 to 2011 to not reached in 2009 to 2017.
Risk Score Developed to Help ID Heart Failure Risk in Leukemia
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Evidence Supports Outpatient Management of Some Children With AML Undergoing Intensive Chemotherapy
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Stem Cell Transplant May Improve Survival in Patients With Relapsed/Refractory ALL
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
Postremission Oral Azacitidine Maintenance Therapy Proposed As a New Standard of Care in Some Patients With AML
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
High Rates of Undetectable MRD Following 2 Years of Ibrutinib-Venetoclax in Certain Patients With CLL/SLL
There is an increasing focus on using the achievement of undetectable MRD in bone marrow as a clinical trial end point in patients with CLL.
Type 2 Diabetes Mellitus in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
Older age, body mass index above 30, and development of drug-induced diabetes mellitus were associated with increased risk for type 2 diabetes mellitus.
Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia
Among patients treated with an acute lymphoblastic leukemia induction regimen, 72% achieved end-of-induction complete remission.
Corticosteroid-Induced Psychiatric Disorders Are Common in Young Patients With Acute Lymphoblastic Leukemia, Lymphoma
This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Outcomes Improved for Patients With AML and MDS Receiving Treosulfan/Fludarabine vs Busulfan/Fludarabine Conditioning Prior to HSCT
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Monitoring Weight in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Patients receiving ibrutinib for chronic lymphocytic leukemia experienced an average weight gain of 2.4 kg at 1 year after therapy initiation.
Quality of Life With Busulfan and Fludarabine Compared With Busulfan and Cyclophosphamide
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
No Influence of Measurable Residual Disease on Haploidentical Transplantation Outcomes in AML
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
Single-Cell RNA Sequencing Characterizes T-Cell Impairment in CAR-T Cells Derived From Patients With CLL
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Exercise Intolerance, Neurocognitive Dysfunction in Survivors of Childhood Acute Lymphoblastic Leukemia
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Reduced Rates of Central Nervous System Relapse in Patients With High-Risk Pediatric ALL
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Acquired von Willebrand Syndrome in Pediatric Patients With Chronic Myeloid Leukemia
Researchers assessed whether high platelet counts in pediatric patients with chronic myeloid leukemia resulted in thrombosis or bleeding.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
19-28z CAR-T Therapy in Children and Young Adults With Relapsed/Refractory ALL: Promising Early Results
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
BTK Inhibition Could Result in Early Risk for Infections
The risk may be transient, as immune function recovered in late phases of treatment.
Measurable Residual Disease Status: A Strong Prognostic Indicator in B-Cell Acute Lymphoblastic Leukemia
Researchers conducted a meta-analysis of 23 studies to determine the influence of measurable residual disease on survival outcomes.
Ibrutinib May Be More Effective Than Ofatumumab in Chronic Lymphocytic Leukemia
Researchers analyzed long-term safety and efficacy data from patients treated with ibrutinib or ofatumumab in the phase 3 RESONATE trial.
Young Patients Report Improved Quality of Life After Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Using EQ-5D and PedsQL, researchers determined the long-term effect of tisagenlecleucel treatment on quality of life for pediatric and young patients with R/R B-cell ALL.
Quality of Life Is Similar in Older Patients Receiving Intensive vs Nonintensive Chemotherapy
Approximately one-third of patients in each treatment group experienced symptoms of depression and anxiety during treatment.
BAFF-R-CAR-T to Overcome Resistance: Q&A With Dr Hong Qin
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Risk of Second Primary Malignancy After Chronic Lymphocytic Leukemia
The risk for second primary malignancy appeared to increase over time in survivors of chronic lymphocytic leukemia compared with the general population.
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
Single Nucleotide Polymorphisms Associated With ALL in Children With Down Syndrome
Researchers conducted a meta-analysis to evaluate possible associations between certain genetic variants and risk for acute lymphoblastic leukemia.
Factors Associated With Low Bone Mineral Density in Blood Cancer Survivors
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
Prognosis of Patients With Chronic Myeloid Leukemia Presenting in Advanced Phase
Factors associated with survival in chronic myeloid leukemia diagnosed in advanced phase or blast crisis included blast count, age, and hemoglobin level.
No Link Between Nutritional Deficiencies, Vincristine-Induced Neuropathy in Pediatric Acute Lymphoblastic Leukemia
Of patients who experienced vincristine-induced neuropathy, approximately half were identified as having undernutrition.
Incidence of Late Events After CAR-T Therapy for Relapsed/Refractory B-Cell Malignancies
Infections occurred in 33 of 54 patients for whom data were available, and 80% of infections were treated in an outpatient setting.
A New Era: Drug Development for Acute Myeloid Leukemia After the Approval of Venetoclax
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
Incidence of GI Adverse Events Associated With CAR-T Therapy for Lymphoma or Leukemia Is Low
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
High Incidence of Severe Respiratory Adverse Events Associated With Induction Therapy in Children, Adolescents With AML
A retrospective study evaluated the incidence of respiratory adverse events in children and adolescents with AML who received induction chemotherapy.
Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype
Presence of a complex karyotype did not affect progression-free or overall survival.
Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
Making Treatment Decisions About Discontinuing TKIs in Chronic Myeloid Leukemia
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Venetoclax Plus Hypomethylating Agents May Offer Treatment Backbone for High-Risk AML
Over half of patients with TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
Maintenance Therapy in Acute Myeloid Leukemia: An Overview
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Outcomes With Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
Familial Risks Associated With Hematologic Malignancies
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
